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Abstract
Dengue virus (DENV) is a mosquito-borne flavivirus, and symptoms of infection range from asymptomatic to the severe
dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). High viral loads correlate with disease severity, and both
type I & II interferons (IFNs) are crucial for controlling viral replication. We have previously reported that signal transducer
and activator of transcription (STAT) 1-deficient mice are resistant to DENV-induced disease, but little is known about this
STAT1-independent mechanism of protection. To determine the molecular basis of the STAT1-independent pathway, mice
lacking STAT1, STAT2, or both STAT1 and STAT2 were infected with a virulent mouse-adapted strain of DENV2. In the first
72 hours of infection, the single-deficient mice lacking STAT1 or STAT2 possessed 50–100 fold higher levels of viral RNA
than wild type mice in the serum, spleen, and other visceral tissues, but remained resistant to DENV-induced death. In
contrast, the double-deficient mice exhibited the early death phenotype previously observed in type I and II IFN receptor
knockout mice (AG129), indicating that STAT2 is the mediator of the STAT1-independent host defense mechanism. Further
studies demonstrated that this STAT2-dependent STAT1-independent mechanism requires the type I IFN receptor, and
contributes to the autocrine amplification of type I IFN expression. Examination of gene expression in the spleen and bone
marrow-derived macrophages following DENV infection revealed STAT2-dependent pathways can induce the transcription
of a subset of interferon stimulated genes even in the absence of STAT1. Collectively, these results help elucidate the nature
of the poorly understood STAT1-independent host defense mechanism against viruses by identifying a functional type I
IFN/STAT2 signaling pathway following DENV infection in vivo.
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Introduction
Interferons (IFNs) play a key role in the defense against viruses
and intracellular bacteria [1–3]. The type I (a/b) IFN receptor is a
heterodimer consisting of the IFN-a/b R1 and R2 chains, binding
all of the closely related IFN-a subtypes, as well as IFN-b. The
type II (c) IFN receptor is a distinct heterodimer, consisting of the
IFN-c R1 and R2 subunits, and it binds IFN-c. Both IFN
receptors signal through the Janus kinase-signal transducer and
activator of transcription (JAK-STAT) pathway [4,5] in which
JAKs phosphorylate STATs, which then translocate to the nucleus
to induce the expression of IFN-stimulated genes (ISGs) [6]. Type
I IFN signaling activates STAT1 and STAT2 to heterodimerize
and associate with interferon regulatory factor-9 (IRF9) to form
IFN-stimulated gene factor-3 (ISGF3), which specifically binds
IFN-stimulated response elements (ISREs) within antiviral gene
promoters. Type II IFN signaling activates STAT1, which
homodimerizes and binds to DNA at c-activated sequence
(GAS) elements.
Studies using mice with targeted disruption of individual IFN
receptor and STAT genes have provided valuable insights into how
type I and II IFNs function during infection by various pathogens.
Mice lacking type I IFN receptor are highly susceptible to infection
by viruses such as vesicular stomatitis virus (VSV), lymphocytic
choriomeningitis virus (LCMV), vaccinia virus (VV), Semliki Forest
virus (SFV), and Theiler’s murine encephalomyelitis virus (TMEV)
[3]. In contrast, mice deficient in type II IFN receptor are unable to
controlinfectionbyintracellularbacteriasuch asListeriamonocytogenes
and Mycobacterium tuberculosis, but are able to mount an effective
response against VSV and SFV [3]. Similarly, STAT2-deficient
mice exhibit reduced responsiveness to type I IFN and are more
susceptible to viral infection [7], whereas STAT1-deficient mice are
defective in their response to both type I and II IFNs and are highly
sensitive to both viral and intracellular bacterial infections [8,9].
These studies highlight the critical roles STAT proteins play in
protection against viral infection, and why STAT proteins are
targeted by viruses to evade antiviral responses.
The flaviviridae family includes dengue (DENV), yellow fever
(YF), West Nile (WNV), and Japanese encephalitis (JEV) viruses,
and represent a group of pathogens that cause significant
morbidity and mortality in humans. Several studies have
demonstrated that flaviviruses interfere with antiviral responses
by targeting STAT1- and STAT2-mediated signaling. Infection
with either WNV or DENV inhibits IFN-mediated STAT1
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JEV and Kunjin virus (a subtype of WNV) infection blocks IFN-a-
induced phosphorylation of both STAT1 and STAT2 in multiple
cell lines [10,11,15]. The antagonists of the antiviral response are
primarily the nonstructural proteins of the flaviviruses, which are
expressed during infection and required for replication. The
expression of NS4B from WNV, YF, or DENV is sufficient for
inhibition of IFN-b-induced STAT1 activation in Vero cells, and
DENV NS2A and NS4A can contribute to this function [13,14].
Similarly, the individual expression of multiple Kunjin virus
nonstructural proteins can inhibit IFN-a-mediated STAT2
activation in Vero cells [11]. In addition, DENV NS5 binds and
targets STAT2 for proteasome-mediated degradation [16–18],
leading to the loss of STAT2 expression observed during DENV
infection in vitro [19].
Although STAT1 is a critical component of both type I and II
IFN-mediated antiviral responses, STAT1-deficient mice are more
resistant to infection with Sindbis virus or murine cytomegalovirus
(MCMV) than type I and II IFN receptor-deficient (AG129) mice
[20], suggesting that IFN receptors also signal through STAT1-
independent mechanisms [21–23]. Previously, we have demon-
strated that STAT1-deficient 129/Sv mice are resistant to DENV–
induceddisease,whereasAG129mice succumbtoDENVinfection,
indicating both STAT1-dependent and STAT1-independent
pathways protect against primary DENV infection [24]. However,
little is known about the mechanism(s) responsible for STAT1-
independentprotectionagainst viralinfections.Inthisstudyweused
mice lacking STAT1, STAT2, both STAT1 and STAT2, or both
STAT1 and the type I IFN receptor to identify STAT2 as a
required mediator of the STAT1-independent antiviral response to
DENV infection via the type I IFN pathway. In STAT1-deficient
mice, STAT2-dependent mechanisms are responsible for the
induction of type I IFN and the expression of a subset of ISGs.
These data demonstrate the importance of IFN-dependent,
STAT1-independent protection against viral infections in vivo,a n d
define key components of protective immunity against DENV.
Results
STAT2 mediates STAT1-independent protection against
DENV infection in mice
Mice lacking type I and type II IFN receptors (AG129), but not
their wild type or single-deficient counterparts, are highly
susceptible to DENV infection and display an early death
phenotype when infected with the DENV serotype 2 (DENV2)
strain S221 [25–27]. In agreement with published studies showing
that type I and type II IFNs restrict DENV infection in mice
[24,26], 12 of 13 AG129 mice died by day 8 following infection
with 10
10 genomic equivalents (GE) (<2610
5 PFU) of the DENV2
strain S221 [28,29] (Figure 1A). Although the STAT1 protein is
a critical component of both type I and II IFN receptor pathways,
mice lacking STAT1 are able to clear DENV infection [24].
Because STAT2-dependent activity has been previously demon-
strated downstream of both type I and type II IFN receptors in the
absence of STAT1 [30,31], we hypothesized STAT2 was involved
in an IFN-dependent STAT1-independent mechanism of protec-
tion against DENV. To assess the contribution of STAT2 to
the STAT1-independent control of DENV infection in vivo,
STAT1
2/2/2
2/2 double knockout mice were generated by
intercrossing single-deficient animals, and also infected with 10
10
GE S221. At this dose of virus, 90–100% of wild type and
congenic single-deficient mice lacking either STAT1 or STAT2
survived DENV infection. However, all mice with a combined
deficiency of STAT1 and STAT2 displayed the early death
phenotype observed in AG129 mice and succumbed to DENV
infection within 4–6 days, demonstrating the importance of
STAT2 to the STAT1-independent mechanism of protection
against DENV infection in vivo (Figure 1A). The median survival
of STAT1
2/2/2
2/2 mice was significantly lower than AG129 at
this virus dose (p=0.0013; **), indicating the absence of both
STAT1 and STAT2 renders these mice more susceptible to
DENV-mediated disease than the combined loss of type I and II
IFN receptors.
To test the limits of this STAT1-independent protection against
DENV, the single-deficient mice were infected with 10-fold (10
11
GE) and 100-fold higher (10
12 GE) doses of S221 and monitored
for survival. Survival proportions of STAT1
2/2 mice challenged
with 10
11 GE DENV remained the same as those infected with
10
10 GE DENV, whereas 4 of 5 STAT1
2/2 animals receiving the
highest dose of virus (10
12 GE) were moribund by day 10
(Figure 1B). In contrast to STAT1
2/2 mice, all STAT2
2/2
animals infected with the equivalent doses of DENV survived
beyond 30 days, indicating that although the STAT1-independent
antiviral response is effective against DENV in vivo, it is less robust
than the antiviral response in the absence of STAT2.
Type I IFN receptor mediates STAT1-independent, STAT2-
dependent signaling in response to DENV infection in
mice
STAT2 function has been primarily linked to the type I IFN
receptor, where it is well-documented to form the ISGF3 complex
with IRF9 and STAT1. However, recent data have indicated that
STAT2 functions not only downstream of type I IFN, but also type
II IFN [30,32], and type III (l) IFN signaling [33], implicating
type I, type II, and type III IFN receptors as potential candidates
for mediating STAT1-independent, STAT2-dependent signaling
during DENV infection. Because we observe the early death
phenotype in AG129 mice, which retain the type III IFN receptor,
we reasoned STAT2 activation was primarily occurring down-
stream of either the type I or type II IFN receptor. Therefore, to
determine which IFN receptors are involved in the STAT1-
independent pathway, double-deficient mice lacking STAT1 and
either the type I IFN receptor (IFNAR) or type II IFN receptor
(IFNGR) were generated by intercrossing the single-deficient
mouse strains. Following intravenous infection with 10
10 GE of
S221, 100% of STAT1
2/2/AR
2/2 mice developed early lethal
disease, whereas none of the STAT1
2/2/GR
2/2 mice suc-
Author Summary
Dengue virus (DENV) is a mosquito-borne pathogen
present in the tropical and sub-tropical regions of the
world, and an estimated 2.5 billion people are at risk of
infection. Interferon (IFN) mediated innate responses in the
host are critical for limiting viral spread following DENV
infection. We have previously demonstrated that mice
lacking STAT1, a key mediator of both type I and II IFN
responses, are not susceptible to DENV-mediated disease.
In this study, we sought to determine the mechanism
responsible for protection against DENV disease in the
absence of STAT1. Using knockout mice, we identify STAT2
as the protein that mediates type I IFN signaling during
DENV infection in the absence of STAT1. The resulting
antiviral response includes amplification of type I IFN and
the expression of interferon stimulated genes. These data
suggest DENV infection is especially sensitive to STAT2-
mediated antiviral responses in vivo, and provide novel
insights towards how IFNs protect against viral infections.
STAT2 Mediates STAT1-Independent Response to DENV
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phenotype of STAT1
2/2/AR
2/2 mice recapitulates that of
STAT1
2/2/2
2/2 mice. This result indicates that the STAT1-
independent, STAT2-dependent mechanism of protection against
DENV infection in mice is mediated by the type I IFN receptor.
The combined loss of STAT1 and STAT2 results in high
viral burden in tissues
To evaluate how STAT1 and STAT2 deficiency impacts the
control of DENV infection, wild type, STAT1
2/2, STAT2
2/2,
STAT1
2/2/2
2/2, and STAT1
2/2/AR
2/2 mice were infected
intravenously with 10
10 GE of S221, and viral RNA levels in
various tissues were measured via qRT-PCR at 6, 12, 18, 24, and
72 hours after infection. Although minimal viral RNA was
detected in each strain at 6 hours post-infection, increasing
viremia was observed in all strains except wild type by 12 hours
post-infection. At 12, 18, and 24 hours post-infection, the high
viremia observed in the single- and double-deficient strains (all
p,0.0005) demonstrates that the combined function of both
STAT1 and STAT2 is required for effective control of viral
replication (Figure 2A). Previous studies have shown that the
spleen is an initial site of DENV replication in mice [28,34], and at
18 and 24 hours post-infection, levels of DENV RNA in the spleen
of each knockout mouse strain were significantly higher than wild
type (14- to 27-fold increase; all p,0.0005) (Figure 2B).
Although each single-deficient mouse strain possessed similar
levels of viral RNA as STAT1
2/2/2
2/2 mice at 12 and 18 hours
Figure 1. Survival of mice following infection with DENV. Survival was monitored for at least 30 days in mice infected i.v. with DENV2 strain
S221. (A) Mice were infected with 10
10 GE (WT n=8; STAT1
2/2 n=12; STAT2
2/2 n=17; STAT1
2/2/2
2/2 n=14; AG129 n=13). Differences in survival
were statistically different (**, p,0.005) between STAT1
2/2/2
2/2 and AG129 mice. (B) Mice were infected with 10
11 GE (n=9) or 10
12 GE of DENV
(n=5). (C) Mice were infected with 10
10 GE (STAT1
2/2/AR
2/2 n=12; STAT1
2/2/GR
2/2 n=8).
doi:10.1371/journal.ppat.1001297.g001
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fold higher in STAT1
2/2 mice than STAT2
2/2 mice by
24 hours. This suggests that early control of DENV replication
requires the combined function of STAT1 and STAT2, but
STAT2-independent mechanism(s) begin to restrict replication by
24 hours post-infection. At 72 hours post-infection, viremia in
both STAT1
2/2 and STAT2
2/2 mice was reduced relative to the
24-hour time point (STAT1
2/2 30-fold, p,0.0001; STAT2
2/2
33-fold, p=0.0019), and the levels of viremia were similar between
these two strains. In contrast to the single-deficient mice, viremia
in STAT1
2/2/2
2/2 mice increased 25-fold between 24 and
72 hours after infection. By 72 hours, viral RNA levels in the
spleen had decreased significantly in all mouse strains, but
remained at least 40-fold higher in STAT1
2/2/2
2/2 mice as
compared to the single-deficient strains.
In the liver, kidney, and small intestine, the later sites of viral
replication in DENV-infected mice [28,34], significantly higher
(100 to 10,000-fold) levels of viral RNA were observed in the
Figure 2. Viral RNA levels in DENV-infected mice. Mice were infected i.v. with 10
10 GE of S221. (A–C) Quantification of DENV RNA in the (A)
serum and (B) spleen at 6, 12, 18, 24 and 72 hours post-infection, and (C) liver, kidney, and small intestine at 72 hours post-infection as determined by
quantitative RT-PCR (6h n=4; 12h n=8; 18h n=8; 24h n=12; 72h n=4). Data are shown as GE per mL of serum or GE per copy of 18S RNA for tissues.
The dotted line represents the limit of detection of the assay for each tissue. (D) Levels of TNF in the serum of DENV-infected mice at 72 hours post-
infection (n=7 per group). Error bars represent the SEM and asterisks denote statistically significant differences (*, p,0.05; **, p,0.005;
***, p,0.0005; ns=not significant). Results are representative of two independent experiments.
doi:10.1371/journal.ppat.1001297.g002
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the single-deficient animals (Figure 2C). Viral burden in
STAT1
2/2/AR
2/2 mice was equivalent to STAT1
2/2/2
2/2
mice in all tissues at 72 hours post-infection (data not shown). In
wild type mice, minimal or no DENV RNA was detected in
these organs. In the single-deficient mice, viral RNA levels in
STAT1
2/2 and STAT2
2/2 animals were similar in the liver,
kidney, and small intestine, although viral load in the kidney was
slightly higher in STAT2
2/2 mice (4-fold; p=0.0105).
Collectively, these data demonstrate that efficient control of
early viral replication requires the combined action of STAT1 and
STAT2. However, each can function independently of the other to
limit viral replication later during infection. Only the combined
absence of both STAT1 and STAT2 ablates the antiviral
response, and results in unrestricted viral replication.
Our previous studies have shown that viral load is directly
linked to high levels of circulating tumor necrosis factor (TNF),
which contributes to the early death phenotype observed in S221-
infected AG129 mice [27,35]. To compare STAT1
2/2/2
2/2
mice to single-deficient and wild type mice, serum TNF levels were
measured by ELISA. Both STAT1
2/2 and STAT2
2/2 mice
possessed similar levels of TNF in the serum at 72 hours post-
infection, which were 4–5 fold higher than that detected in wild
type mice (Figure 2D). However, levels of serum TNF in the
single-deficient strains remained significantly lower (.20-fold)
than in STAT1
2/2/2
2/2 mice, indicating that control of viral
replication by STAT1 or STAT2 alone results in reduced TNF
expression during DENV infection, and is consistent with the
survival studies where only double-deficient animals were
susceptible to DENV-induced death.
Type I IFN expression in response to DENV infection is
delayed in STAT-deficient mice
Based on the survival data indicating that STAT1-independent
protection is mediated via type I IFN signaling, we next examined
type I IFN levels in infected mice, as expression of type I IFN is
partially dependent upon a positive feedback mechanism [2].
Specifically, type I IFN levels in wild type and single-deficient
mice were compared to STAT1
2/2/2
2/2 mice, which are not
expected to possess the positive feedback loop. Serum levels of
IFN-a and IFN-b in wild type, STAT1
2/2, STAT2
2/2, and
STAT1
2/2/2
2/2 mice were measured by ELISA between 0 and
24 hours post-infection. High levels of serum IFN-a were present
in wild type mice by 12 hours post-infection, and these levels
diminished between 18 and 24 hours after infection (Figure 3A),
consistent with our previous observations in wild type C57BL/6
mice following DENV infection [28]. However, robust IFN-a
production in both STAT1
2/2 and STAT2
2/2 mice was delayed
until 18 hours following infection, and STAT1
2/2 mice exhibited
decreased expression of IFN-a compared with STAT2
2/2 mice.
Serum IFN-a levels in STAT1
2/2/2
2/2 mice followed the same
kinetics as STAT1
2/2 mice, including increased expression at
18 hours post-infection. However, despite similar levels of viremia
detected in both strains at 24 hours post-infection (Figure 2A),
IFN-a in STAT1
2/2 mice remained elevated but in STAT1
2/2/
2
2/2 mice it decreased to the level at or below the limit of
detection (p,0.0001). Similar trends were observed for IFN-b
production following DENV infection (Figure 3B), including
delayed induction in the knockout strains relative to wild
type mice, and elevated IFN-b levels in STAT1
2/2 but not
STAT1
2/2/2
2/2 mice at 24 hours. Together, these results
demonstrate that the combined function of STAT1 and STAT2
is required for maximum early induction of type I IFN in response
to DENV infection. The presence of either STAT1 or STAT2
alone is also sufficient to drive type I IFN expression, but with
delayed kinetics when compared to an intact IFN signaling
pathway. Additionally, the difference in IFN levels between
STAT1
2/2 and the double knockout mice at 24 hours shows
that a STAT2-dependent mechanism contributes to type I IFN
expression in the absence of STAT1.
Figure 3. Levels of type I IFN in the serum of DENV-infected mice. Mice were infected i.v. with 10
10 GE of S221, and serum collected at 6, 12,
18, or 24 hours post-infection. Levels of (A) IFN-a and (B) IFN-b in the serum were determined by ELISA (n=4–6 mice per group). Error bars represent
the SEM. Results are representative of two independent experiments.
doi:10.1371/journal.ppat.1001297.g003
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during DENV infection
To further define the mechanisms by which type I IFN
receptor-STAT2 signaling protects against DENV infection in vivo,
we next examined gene expression in the spleens of S221-infected
mice using the Type I IFN-related RT
2 Profiler PCR Array
(SABiosciences/QIAGEN). RNA from whole spleens was ana-
lyzed and fold-induction calculated by comparing infected mice to
naı ¨ve mice of the corresponding strain. Of the 84 genes in the
array, 31 (36.9%), 16 (19.0%), 22 (26.2%), and 7 (8.3%) genes,
respectively, were induced 3-fold over naı ¨ve in wild type,
STAT1
2/2, STAT2
2/2, and STAT1
2/2/2
2/2 mice at 12 hours
post-infection (Figure 4A), and the number of genes upregulated
was similar at 24 hours post-infection for each mouse strain.
Genes that were induced in STAT1
2/2/2
2/2 mice identified
ISGs that were upregulated independently of either STAT1 or
STAT2. These ISGs included Ifna2, Ifna4, and Ifnb1, which were
induced to high levels in all four strains at 12 hours (.1000-fold)
and 24 hours (.100-fold) post-infection (Table S1), and likely
represent early IRF3-mediated gene expression [36].
A number of ISGs were identified that were induced .3-fold
over uninfected controls in STAT1
2/2 mice, but were not
induced in STAT1
2/2/2
2/2 mice (Figure 4A), revealing that a
STAT2-dependent mechanism can drive the expression of
multiple ISGs in the absence of STAT1. In addition, several
genes that were weakly upregulated in STAT1
2/2/2
2/2 mice
(Cxcl10, Mx2, Isg15) were induced 6- to 28-fold higher in
STAT1
2/2 mice than in the double knockout, suggesting that
the STAT1-independent pathway heavily contributes to the
regulation of these genes as well. Genes upregulated in
STAT1
2/2 mice were then compared to wild type and
STAT2
2/2 mice at 12 hours (12 genes) (Figure 4C) and
24 hours (12 genes) (Figure 4D) post-infection. At the 12 hour
time point, more than half of the genes in this group displayed at
least 3-fold higher induction in wild type mice than in STAT1
2/2
mice. However, by 24 hours post-infection, the gene induction
levels observed in wild type and STAT1
2/2 mice were similar
(,2-fold) except for the highly elevated Oas1a gene in STAT1
2/2
mice. This increased upregulation in STAT1
2/2 mice at 24 hours
is consistent with the elevated levels of type I IFN observed at
24 hours post-infection (Figure 3). Two genes upregulated in
STAT1
2/2 mice, Mx1 and Eif2ak2 (PKR), were not induced in
STAT2
2/2 mice, suggesting that STAT2 is required for their
expression in response to DENV infection. Conversely, Gbp1 and
Gbp2 were induced more efficiently in STAT2
2/2 animals than in
STAT1
2/2 mice, and several additional genes in this array were
induced in STAT2
2/2 and wild type but not STAT1
2/2 mice at
both timepoints. (Table S1). Collectively, these results demon-
strate that a STAT1-independent pathway regulates the expres-
sion of ISGs in a STAT2-dependent manner during DENV
infection in vivo.
In order to perform more mechanistic studies, bone marrow-
derived macrophages (BMMs) were isolated from wild type and
knockout mice, and evaluated in vitro. BMMs were chosen because
cells of the monocyte/macrophage lineage are presumed to be one
of the major cell types that support DENV replication in humans
and mice [37–39]. BMMs were infected with S221 (MOI=5), and
gene induction at 12 and 24 hours post-infection was evaluated
using the RT
2 Profiler PCR Array (Table S2). A majority of genes
induced in the spleen were also upregulated in BMMs from each
strain (29/31 genes in wild type; 13/16 in STAT1
2/2; 5/7 in
STAT1
2/2/2
2/2), indicating that gene regulation of ISGs is
similar between the spleen and BMMs following DENV infection
(Figure 4B), and validating the use of BMMs as a suitable in vitro
model for these studies.
STAT2 does not require STAT1 for type I IFN-mediated
activation in mouse bone marrow-derived macrophages
To confirm activation of STAT2 in the absence of STAT1,
phosphorylation and nuclear localization of STAT2 was examined
in BMMs. Type I IFN signaling activates STAT2 via phosphor-
ylation of a tyrosine residue (Y689), which is required for its
association with STAT1 and incorporation into the transcription-
ally active complex ISGF3 [40]. BMMs isolated from wild type,
STAT1
2/2, STAT1
2/2/2
2/2, and STAT1
2/2/AR
2/2 mice
were stimulated with recombinant IFN-b for 15 minutes, and the
phosphorylation status of STAT2 was examined via Western blot
(Figure 5A). As expected, both STAT1 and STAT2 were
phosphorylated in wild type cells. Phosphorylation of STAT2
was observed in STAT1
2/2 but not STAT1
2/2/AR
2/2 cells,
although the basal level of STAT2 was lower in both STAT1
2/2
and STAT1
2/2/AR
2/2 cells than in wild type cells. These results
show that STAT2 activation can occur in the absence of STAT1
following type I IFN stimulation.
STAT2 activation occurs independently of STAT1
following DENV infection of mouse bone marrow-
derived macrophages
In addition to type I IFN, cytokines produced during DENV
infection are able to activate JAK-STAT signaling, including IL-2,
IL-4, IL-6, IL-10, and IFN-c [35,41,42]. To examine STAT2
activation in the context of DENV infection, BMMs were
incubated with serum taken from wild type mice infected with
S221, and analyzed by Western blot (Figure 5B). Similar to
recombinant IFN-b, the infected mouse serum induced both
STAT1 and STAT2 phosphorylation in wild type cells. Phos-
phorylation of STAT2 was detected in STAT1
2/2 but not
STAT1
2/2/AR
2/2 BMMs, indicating that activation of STAT2
in these cells is primarily dependent upon type I IFN signaling.
To verify that phosphorylation of STAT2 occurs in the absence
of STAT1 during DENV infection, BMMs were infected with
S221 and STAT phosphorylation was examined at 12, 18, and
24 hours post-infection (Figure 5C). Consistent levels of STAT1
phosphorylation were detected at all time points in wild type cells,
whereas levels of phosphorylated STAT2 were highest at 12 hours
after infection and decreased over time. Phosphorylated STAT2
was also detected at the 12 hour and 18 hour time points in
STAT1
2/2 cells, but not in STAT1
2/2/AR
2/2 cells.
To further confirm STAT1-independent activation of STAT2,
wild type and STAT1
2/2 BMMs were incubated with serum from
either naı ¨ve or S221-infected wild type mice for 1 hour, and
nuclear localization of STAT2 was examined using immunoflu-
orescence (Figure 5D). Although the staining pattern within the
nucleus appeared different between the two strains, STAT2 was
observed in the nuclei of both wild type and STAT1
2/2 cells.
Taken together, these results indicate that STAT2 is activated via
type I IFN receptor signaling during DENV infection, even in the
absence of STAT1.
STAT2 directly associates with ISG promoters following
DENV infection
In response to type I IFN signaling, the STAT1:STAT2:IRF9
(ISGF3) complex translocates to the nucleus to bind ISREs found
in the promoters of many ISGs. To determine whether STAT2 is
directly involved in the transcriptional regulation of ISGs in the
absence of STAT1, chromatin immunoprecipitation (ChIP)
STAT2 Mediates STAT1-Independent Response to DENV
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Gene targets Oas1a, Oas1b, and IRF7 were chosen from ISGs that
were expressed in wild type and STAT1
2/2 BMMs, but not in
STAT1
2/2/2
2/2 double deficient cells as determined by the
PCR array analysis (Table S2). DNA from S221-infected wild
type, STAT1
2/2 and STAT1
2/2/2
2/2 BMMs was harvested at
12 and 24 hours post-infection, and quantitative PCR was
performed on anti-STAT2 precipitated DNA using primer pairs
specific to ISREs located in the promoters of these genes.
Following DENV infection, increased binding of STAT2 to all
Figure 5. Activation of STAT1 and STAT2 in bone marrow-derived macrophages. (A–C) Whole cell lysates were generated from bone
marrow-derived macrophages that were isolated from WT, STAT1
2/2, STAT1
2/2/2
2/2, or STAT1
2/2/AR
2/2 mice and treated with (A) 1000U/mL
recombinant murine IFN-b for 15 min, (B) serum from naı ¨ve (N) or S221-infected (I) mice for 1 hour, or (C) infected with S221 (MOI=5) for the times
indicated. Protein levels of STAT1, phosphorylated STAT1, STAT2, phosphorylated STAT2, and beta-actin were examined by Western blot. (D) Nuclear
localization of STAT2 in bone marrow-derived macrophages isolated from WT and STAT1
2/2 mice, and treated with serum from naı ¨ve (N) or S221-
infected (I) mice for 1 hour. STAT2 (red), and DAPI (blue). Original magnification, 6400. Images are representative of each strain. Data are
representative of two or more individual experiments.
doi:10.1371/journal.ppat.1001297.g005
Figure 4. Comparison of ISG Induction in DENV-infected mice. Gene induction evaluated using the RT
2 Profiler PCR Array (Mouse IFN-a/b
Response Array; SABioscience). (A,B) Annotated gene expression of transcripts with a difference in expression of 3-fold or more over naı ¨ve
(upregulation-black; downregulation-white) at 12 and 24 hours post-infection of (A) spleens isolated from wild type, STAT1
2/2, STAT2
2/2, and
STAT1
2/2/2
2/2 mice infected with S221, and (B) BMMs isolated from wild type, STAT1
2/2, and STAT1
2/2/2
2/2 mice infected with S221 (MOI=5). (C,
D) Gene induction in the spleen expressed as fold-increase over naı ¨ve for each strain at (C) 12 hours and (D) 24 hours post-infection. Data represent
mean fold-induction of three animals per strain at each timepoint.
doi:10.1371/journal.ppat.1001297.g004
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2/2
BMMs when compared to naı ¨ve cells (Figure 6A–C). STAT2
binding to the Oas1a promoter in STAT1
2/2 cells was only
significantly enriched at 24 hours post-infection, while Oas1b
and IRF7 had significant enrichment at both time points. In
particular, the binding activity of STAT2 to the Oas1b promoter in
STAT1
2/2 cells almost matched that of wild type cells
(Figure 6B). Nearly undetectable DNA enrichment was observed
for all three genes in STAT1
2/2/2
2/2 cells, providing evidence
of the antibody’s specificity for STAT2. Taken together, these
results demonstrate that STAT2 binds to the promoters of ISGs in
the absence of STAT1, providing further evidence of a direct role
for STAT2 in the regulation of antiviral responses.
Discussion
STAT1 was originally described as a transcription factor
essential for type I and II IFN signaling, and initial studies
described STAT1
2/2 cells and mice as unresponsive to both type
I and II IFN [8,9]. However, later studies in STAT1
2/2 mice
infected with Sindbis virus or MCMV revealed the existence of a
STAT1-independent antiviral mechanism [20]. Similarly, we have
demonstrated that a STAT1-independent IFN response confers
protection from DENV infection in mice [24]. Given that both
type I and type II IFN-mediated responses restrict DENV
infection in vitro and in vivo [25,26,43,44], we were interested in
defining the mechanism of this STAT1-independent protection.
In this study, we demonstrated that the combined loss of both
STAT1 and STAT2 in mice resulted in early death following
DENV infection. These results recapitulated the early death
phenotype of AG129 mice and implied that the increased DENV
susceptibility in STAT1
2/2/2
2/2 mice was due to the loss of type
I and II IFN signaling. Conversely, both STAT1 and STAT2
single-deficient mice survived infection with DENV at this same
dose of virus, suggesting there are sufficient compensatory
mechanisms that protect against DENV infection in the absence
of either one of these STAT proteins. While the susceptibility of
the STAT1
2/2/IFNAR
2/2 double knockout mice to DENV
infection indicated that STAT2 was functioning downstream of
type I IFN signaling, the survival of STAT1
2/2/IFNGR
2/2 mice
confirmed the potency of STAT2-mediated protection. IFNAR
2/2/
IFNGR
2/2 (AG129) mice do not survive infection, yet
STAT1
2/2/IFNGR
2/2 mice remain healthy, demonstrating
that STAT2 alone provides sufficient signaling via the type I
IFN pathway for a functional antiviral response, despite the
absence of both STAT1 and type II IFN signaling. However,
STAT1
2/2 mice challenged with a 100-fold higher dose of virus
succumbed to DENV infection, indicating that STAT2-mediated
protection can be overcome. In contrast, STAT2
2/2 mice
remained healthy at the highest dose tested, most likely due to
an intact type II IFN signaling pathway, and indicating that
functional STAT1 plays a larger role in anti-DENV responses
than STAT2. This claim is supported by the viral load data, where
tissue viral burden in STAT2
2/2 mice remained slightly lower
than their STAT1
2/2 counterparts at multiple timepoints
following infection. Although little difference was observed in
tissue viral load between the single deficient STAT mice and the
double knockouts during the first 24 hours following infection,
both STAT1 and STAT2 were able to function independently of
each other to provide significant protection in all tissues by
72 hours post infection. Consistent with the kinetics of type I IFN
expression, the viral load data suggest that antiviral responses in
the single deficient mice are delayed compared to wild type mice.
This delayed response is likely due to the inability to form ISGF3
(STAT1:STAT2:IRF9), the primary transcription complex asso-
ciated with type I IFN signaling, resulting in suboptimal activation
of the type I IFN signaling pathway. Despite the inability to form
ISGF3, STAT1
2/2 mice still induced a subset of ISGs in response
to DENV infection that were not upregulated in STAT1
2/2/
2
2/2 mice. The PCR array data, although far less comprehensive
than genome-wide analysis, provided evidence that the STAT1-
independent pathway mediates protection through the expression
of antiviral genes.
One concern with the PCR array approach in whole spleens is
that total RNA was isolated from a heterogeneous cell population,
and differences in cell type distribution between strains or naı ¨ve
versus infected mice could complicate analysis. To address this,
PCR arrays were performed using BMMs from the different
knockout strains. Although the kinetics and efficiency of infection
are likely to be different in vivo versus in vitro, the overall pattern of
ISG induction in BMMs was similar to the spleen, confirming that
our gene expression data were not biased by using whole tissue.
Figure 6. Association of STAT2 protein with ISG promoters. ChIP analysis using a STAT2-specific antibody in bone marrow-derived
macrophages isolated from WT, STAT1
2/2, or STAT1
2/2/2
2/2 mice and infected with S221 (MOI=5) for 12 and 24 hours. Enrichment was measured
by quantitative PCR, and percent of input DNA was determined by comparing cycle threshold value (Ct) obtained with immunoprecipitated DNA and
Ct value obtained from input DNA. Genes analyzed were (A) Oas1a (B) Oas1b and (C) Irf7. Error bars represent the SEM, and asterisks denote
statistically significant differences (*, p,0.05; ***, p,0.0005). Results are representative of two independent pull-down experiments.
doi:10.1371/journal.ppat.1001297.g006
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mouse spleens revealed that little difference exists in cellular
composition between STAT1
2/2 and STAT1
2/2/2
2/2 mice
(Figure S1), whose relative differences in gene induction were
compared to identify STAT1-independent ISGs.
Prior to this work, several key studies demonstrated that STAT2
can function in the absence of STAT1. Hahm and colleagues
showed that dendritic cell maturation is impaired in a IFN-b-
dependent, STAT2-dependent manner following infection of
pluripotent bone marrow cells by measles virus (MV) and LCMV
[31]. Although this was the first description of a STAT2-mediated
STAT1-independent phenotype, the focus of this work was on an
immunosuppressive rather than an antiviral phenotype. Sarkis and
colleagues first demonstrated that STAT2 was required for IFN-a-
induced expression of several antiviral genes in cultured liver cells,
including Mx1, PKR, and Isg15 [45], independently of STAT1
expression. However, the authors inferred this STAT2-dependent
pathway was liver-specific since they could not carry these
observations into cells other than human hepatoma cells.
Similarly, Lou and colleagues also described STAT1-independent
gene induction of RIG-G by STAT2 in response to type I IFN, in
an in vitro system that required the over-expression of IRF9 [46].
The present study extends these bodies of work by demonstrating
that STAT2 can mediate antiviral responses independently from
STAT1 through direct association with ISG promoters, including
antiviral genes that are otherwise regulated by ISGF3, not just
ISGs that have been demonstrated to be STAT2-dependent. To
our knowledge, this is the first report of STAT2 functioning
downstream of type I IFN signaling in the absence of STAT1,
which results in a functional antiviral response in vivo.
ChIP analysis confirmed the association of STAT2 protein with
antiviral gene promoters, implying that STAT2 has a direct role in
transcriptional regulation, but the exact mechanism of how
STAT2 mediates IFN signaling remains to be determined.
Although it possesses a strong transactivation domain, STAT2
binds DNA poorly, suggesting that STAT2 does not function
alone [47]. IRF9 (p48) provides both DNA binding and sequence
specificity functions to the ISGF3 complex [47], and its
involvement has been implicated in STAT1-independent mech-
anisms [45,46]. Therefore, the most likely candidate for an
alternative STAT2 complex includes IRF9. In addition to ISGF3,
several complexes containing STAT2 have been described,
including STAT2:3 and STAT2:6 heterodimers, and STAT2:2
homodimers [47–49]. However, further biochemical studies will
be required to identify the components of this alternative
transcriptional complex that functions in the absence of STAT1.
The promoter sequence element that binds this alternative
complex also remains unknown, and likely depends upon other
binding partners. The ISGs identified by PCR array in this study
represented a subset of ISGs induced in wild type mice, suggesting
a novel binding element is unlikely. A more comprehensive study
of gene modulation other than the PCR array, such as full
microarray or ChIP-seq, should shed light on how ISRE, GAS,
and other promoter elements are regulated in the absence of
STAT1.
It is important to consider the difference between mouse and
human STAT2 when interpreting the results of our studies. While
the other STAT proteins have a high degree of sequence
homology between the two species, the C-terminal transactivation
domains between human and mouse STAT2 are completely
divergent, so it is unknown whether mouse and human STAT2
function similarly when taken out of the context of ISGF3.
However, in vitro studies have suggested mouse STAT2 is
functionally analogous to human STAT2 in ISGF3 formation,
ISRE activation, and biological response to type I IFN [50]. The
relevance of species-specific STAT2 has recently been demon-
strated in terms of DENV infection: the NS5 protein of DENV
binds and targets human STAT2 for proteasomal degradation to
inhibit type I IFN responses [16,18]. Ashour and colleagues have
recently demonstrated that this targeting is species specific, and
murine STAT2 is resistant to NS5-mediated degradation [17]. In
the studies presented here, basal expression of STAT2 was
unaffected in BMMs infected with DENV, but the level of
infection of our BMMs may be as low as 1% (unpublished
observation), suggesting NS5 has little direct effect upon STAT2 in
our culture system.
In this study, we have identified STAT2 as a key component of
the STAT1-independent mechanism of protection against DENV
infection in mice, and demonstrated that both STAT1 and
STAT2 possess the ability to independently limit the severity of
DENV pathogenesis. For many viruses, inhibition of STAT-
mediated signaling is a major mechanism to evade antiviral
responses. Our data suggests that DENV-mediated inactivation of
STAT1 function alone is not sufficient to neutralize antiviral
responses, emphasizing the importance of DENV mechanisms to
specifically target host STAT2 function. Increasing evidence
suggests that the relative ability of flaviviruses to subvert STAT
signaling, including DENV, WNV, JEV, and Kunjin viruses, may
be a contributing factor to their virulence [51–54]. In conjunction,
epidemiological studies have revealed that selection for virulent
DENV strains occurs in both humans and mosquitoes [55–57]. A
more detailed understanding of how DENV causes specific
pathologies, even in an immunodeficient setting (as in STAT1
2/2/
2
2/2 mice), may offer additional insight regarding prevention of
human DENV-induced disease from both current and newly
emerging strains.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health, the US
Public Health Service Policy on Humane Care and Use of
Laboratory Animals, and the Association for Assessment and
Accreditation of Laboratory Animal Care International (AAA-
LAC). All experimental procedures were pre-approved and
performed according to the guidelines set by the La Jolla Institute
for Allergy and Immunology Animal Care and Use Committee.
Cells and viruses
Generation and preparation of DENV2 strain S221 has been
described previously [28,35]. Briefly, S221 is a triple-plaque-
purified clone of D2S10, which was generated by alternative
passage between AG129 mice and C6/36 mosquito cells. Viral
stocks used for these studies were grown in C6/36 mosquito cells
and concentrated by ultracentrifugation [34]. Genome equivalents
(GE) were quantified by real-time reverse transcription-PCR (RT-
PCR) and infectious titer determined by plaque assay on BHK-21
cells, as previously described [34].
Mouse experiments
Wild type (WT) 129/Sv/Ev were purchased from Taconic
Farms. STAT1
2/2 129/Sv/Ev mice bearing a deletion in the
DNA binding domain of the STAT1 gene were obtained from Dr.
Joan Durbin (Ohio State University, Columbus, OH). STAT2
2/2
129/Sv/Ev mice were obtained from Dr. Christian Schindler
(Columbia University, New York, NY). All mice were bred and
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Institute for Allergy and Immunology (LIAI). For all experiments,
sex-matched mice at 5 to 6 weeks of age were infected
intravenously with 10
10 GE (<2610
5 PFU) of S221 diluted into
200mL PBS with 5% FCS. For survival studies, mice were
sacrificed when moribund or at the first signs of paralysis.
Viral RNA harvest and quantification
Mice were euthanized via isoflurane inhalation and blood was
collected by cardiac puncture. Mice were perfused with 60mL
phosphate-buffered saline (PBS) and tissues collected into
RNALater (QIAGEN). Tissues were homogenized for 3 minutes
at 4uC in 1mL tissue lysis buffer (QIAGEN RLT Buffer) using a
Mini-beadbeater-8 (BioSpec Products). Liver and small intestine
homogenates were diluted 5-fold and homogenized for 3
additional minutes. RNA was isolated from tissue homogenates
using the RNeasy minikit (QIAGEN) and from 30mL serum using
the QIAmp viral RNA minikit (QIAGEN) according to manufac-
turer’s instructions, eluted and stored at 280uC until analysis.
Quantitative RT-PCR to detect DENV and 18S was performed as
previously described [34]. Viral load is expressed as GE per mL in
serum, or GE normalized to copies of 18S in tissues.
ELISA
Serum from infected or naı ¨ve animals was analyzed using either
a mouse TNF-a ELISA Ready-Set-Go kit (eBioscience) or mouse
IFN-a ELISA and IFN-b ELISA (PBL Technologies), all
according to the manufacturers’ instructions. The IFN-a ELISA
kit detects all subtypes of IFN-a according to the manufacturer.
Isolation and DENV infection of bone marrow-derived
macrophages
To generate bone marrow-derived macrophages, bone marrow
from femur and tibia of 5- to 7-week old mice were isolated and
cultured for 6–7 days in RPMI 1640 (10% fetal calf serum,
penicillin, streptomycin, HEPES, sodium pyruvate, 55mM b-
mercaptoethanol) in the presence of 100ng/mL murine macro-
phage stimulating factor (M-CSF) (PeproTech). On day 6–7 of
culture, cells were treated with either 1000U recombinant murine
IFN-b (PBL Biomed) for 15 minutes, 100mL serum obtained from
DENV2-infected wild type mice for 60 minutes, or infected with
S221 (MOI=5), followed by harvesting of the cells at 0, 12, 18, or
24 hours post-infection.
Western blot analysis
Immediately following treatment, bone marrow-derived mac-
rophages (10
6 cells) were lysed in Western lysis buffer (25mM Tris-
HCl, 150mM NaCl, 1% NP40) in the presence of protease
inhibitor cocktail (Sigma), Phosphatase Inhibitor Cocktail Set II
(Calbiochem), and 1mM okadaic acid (Sigma). Samples were
resolved on 8% SDS-polyacrylamide gels, transferred overnight to
PVDF (Millipore) at 4uC, and probed overnight with the following
antibodies: anti-STAT1 and anti-P701-STAT1 (Cell Signaling),
anti-STAT2 (Millipore), anti-P689-STAT2 (Santa Cruz Biotech),
and anti-beta-actin (Sigma). Blots were incubated with HRP-
conjugated secondary antibody (Pierce) and visualized with
Western Lightning Plus-ECL (Perkin Elmer).
PCR Arrays
Splenic RNA was harvested from spleens as described above.
Bone marrow-derived macrophage RNA was harvested using
Trizol reagent (Invitrogen) and further purified with the RNeasy
minikit (QIAGEN). To remove genomic DNA contaminants, 1mg
total RNA was treated with 0.5 units DNAse (Invitrogen) for
15 minutes at 20uC and then 8 minutes at 70uC to inactivate
DNAse enzyme. cDNA was then generated using the RT
2 First
Strand kit (SABioscience) according to the manufacturer’s
protocol. Newly synthesized cDNA was loaded onto RT
2 Profiler
(SABioscience) 384-well PCR array plates (PAMM-016) and
amplified on the LightCycler 480 PCR system (Roche) for 40
cycles. The resulting threshold cycle values (Ct) were uploaded
onto the SABioscience website (http://www.sabiosciences.com/
pcr/arrayanalysis.php) and relative levels of gene expression (fold
differences) were calculated using the provided software. Ct values
$35 cycles were considered undetectable.
Immunofluorescence
Bone marrow-derived macrophages were seeded on glass
coverslips and treated with infected mouse serum for 1 hour.
Following treatment, cells were fixed in 3% paraformaldehyde for
30 minutes, permeabilized in 0.1% Triton X-100 for 10 minutes,
and blocked in 20% purified goat serum (Pierce) for 1 hour. Cells
were washed, incubated with anti-STAT2 antibody (obtained
from Dr. Christian Schindler) followed by DyLight 649-labeled
goat anti-rabbit IgG (Jackson Immunoresearch). Nuclei were
counterstained with DAPI, and viewed using a Marianas
deconvolution fluorescence microscope (3i).
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed essentially as described [58]. Bone
marrow-derived macrophages (3610
6 cells) were fixed in 1%
formaldehyde and lysed in 50mM Tris-HCl, pH 8.0, 10mM
EDTA, 1% SDS on ice for 5 minutes. Lysates were sonicated and
diluted with 9 parts 50mM Tris-HCl, pH 8.0, 167mM NaCl,
1.1% Triton X-100, and 0.11% sodium deoxycholate. 10mgo f
DNA was used for each immunoprecipitation. Rabbit polyclonal
antibody specific for murine STAT2 (Schindler) was used to
precipitate STAT2-DNA complexes. Immunocomplexes were
bound to protein G-agarose beads (Pierce Thermo Scientific),
washed 5 times, and eluted by incubating beads at 65uC overnight
in 10mM Tris-HCl, 5mM EDTA, 300mM NaCl, 0.5% SDS.
Eluted DNA was treated with RNAse A and proteinase K, and
purified using the QIAquick PCR Purification kit (QIAGEN).
Quantitative SYBR Green PCR was performed on the Light-
Cycler 480 PCR System (Roche) for 45 cycles. Primer sequences
used: Oas1a(+) AAACCCCAAGAAAGCCAGAT, Oas1a(2)
CTCCCAGCCTAGCTGAAATG; Oas1b(+) CTGTTCAGAA-
GCCCTAACGC; Oas1b(2) AGGTCAGCACAGAAGCTGGT;
IRF7(+) TGGGATCTGAGTAAGGGTCG; IRF7(2) GCCAA-
GGTGGCTGTAGATGT.
Flow cytometry
Mice were infected i.v. with 10
10 GE of S221. Single-cell
suspensions were prepared from naı ¨ve and infected spleens
harvested at 12 and 24 hours post-infection with Spleen
Dissociation Medium (Stem Cell Technologies) (n=3 per group).
The following antibodies were used: Alexa Fluor 647-conjugated
anti-B220 (HI30; Biolegend) and anti-F4/80 (Cl:A3-1; Biolegend);
eFluor 450-conjugated anti-CD4 (RM4-5; eBioscience) and anti-
Gr-1 (RB6-8C5; eBioscience); fluorescein isothiocyanate-conjugat-
ed anti-CD3e (145-2C11; eBioscience) and anti-CD11b (M1/70;
BD Pharmingen); phycoerythrin-conjugated anti-CD11c (N418;
eBioscience); phycoerythrin-indotricarbocyanine-conjugated anti-
CD8a (53-6.7; BD Pharmingen); and peridinin chlorophyll
protein-cyanine 5.5-conjugated anti-B220 (RA3-6B2; BD Phar-
mingen) and anti-CD49b (DX5; Biolegend). Samples were
collected on FACS LSR II (BD Biosciences) and were analyzed
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CELL XR (Beckman Coulter).
Statistical analysis
For all studies, data were analyzed by Prism 5 software
(GraphPad Software). For survival studies, Kaplan-Meier survival
curves were analyzed by log rank test. Viral load, cytokine ELISA,
and ChIP data were analyzed using the unpaired t test.
Supporting Information
Figure S1 Cell composition of spleens following DENV
infection. Percentage of various live cell types in splenocytes
isolated from mice infected with 10
10 GE of S221 at 0 hours
(naı ¨ve), 12 hours and 24 hours post-infection. Each were classified:
(A) macrophages-CD11b
+F4/80
+, (B) CD4
+ T cells-CD3
+CD4+,
(C) CD8
+ T cells-CD3
+CD8
+, (D) natural killer cells-
CD3
2CD49b
+, (E) NK T cells-CD3
+CD49b
+, (F) B cells-B220
+,
(G) neutrophils-CD11b
+Gr-1
+, (H) plasmacytoid dendritic cells-
CD11c
+B220
+, and other dendritic cells-CD11c
+B220
2. (I) Total
live cell counts for each strain 6 SEM. Error bars represent the
SEM and asterisks denote statistically significant differences (*,
p,0.05; **, p,0.005). Results are mean values from three
animals.
Found at: doi:10.1371/journal.ppat.1001297.s001 (5.04 MB TIF)
Table S1 Quantitative PCR Array data from infected spleens.
Complete list of genes examined in the IFN-a/b related PCR
array (PAMM-016; SABiosciences). Fold change was calculated
based upon naı ¨ve control mice for each individual strain using
software provided by the manufacturer (see Material and
Methods).
Found at: doi:10.1371/journal.ppat.1001297.s002 (5.41 MB TIF)
Table S2 Quantitative PCR Array data from infected bone
marrow derived macrophages. Complete list of genes examined in
the IFN-a/b related PCR array (PAMM-016; SABiosciences).
Fold change was calculated based upon naı ¨ve control mice for
each individual strain using software provided by the manufac-
turer (see Material and Methods).
Found at: doi:10.1371/journal.ppat.1001297.s003 (5.31 MB TIF)
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